Comparison of 0.25% and 0.125% bupivacaine in hyperthermic intraperitoneal chemotherapy (HIPEC): a single-center experience
Annals of Middle Eastern Medicine · 25.10.2026 · 2 (5) · 682-688
DOI: 10.24911/amem.15-3168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Middle Eastern Medicine, online erschienen am 25.10.2026. Verfasst von Rasheed Alhabib und 5 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) causes severe postoperative pain; thoracic epidural analgesia is recommended, but the optimal epidural bupivacaine concentration has not been studied in this setting. We compared 0.25% and 0.125% epidural bupivacaine after CRS + HIPEC.
Methodology: This retrospective cohort study included 77 adults who underwent CRS + HIPEC at a tertiary care center between January 2017 and December 2021. All received epidural fentanyl 2 mcg/ml with 0.125% (n = 59) or 0.25% (n = 18) bupivacaine (non-randomized). Pain severity was categorized from visual analog scale assessments. Secondary outcomes were sensory block level, supplementary intravenous (IV) analgesia, patient-controlled analgesia (PCA), and adverse effects. Groups were compared using Fisher’s exact or Fisher–Freeman–Halton exact tests.
Results
Mild pain occurred in 11/18 patients (61.1%) receiving 0.25% and 19/59 (32.2%) receiving 0.125% bupivacaine (exploratory risk difference 28.9 percentage points; 95% confidence interval 3.1–50.3), moderate pain in 7 (38.9%) and 38 (64.4%), and severe pain in 0 and 2 (3.4%), respectively. The overall pain-severity distribution did not differ significantly (p = 0.101), nor did sensory block level (p = 0.284), supplementary IV analgesia (p = 0.272), PCA use (p = 1.000), or nausea and vomiting (p = 0.556). No patient had pruritus or
motor complications.
Conclusion
No statistically significant differences in pain outcomes or adverse effects were detected between the two concentrations. The small, unequal, and non-randomized groups preclude conclusions about equivalence or superiority; adequately powered prospective studies are needed.
Zitieren
APA
Alhabib, R., Tulbah, M., Albishri, F. S., Aldammas, F. K., Sallam, M. S., & Alotaibi, A. M. (2026). Comparison of 0.25% and 0.125% bupivacaine in hyperthermic intraperitoneal chemotherapy (HIPEC): a single-center experience. Annals of Middle Eastern Medicine, 2(5), 682-688. https://doi.org/10.24911/amem.15-3168
Vancouver
Alhabib R, Tulbah M, Albishri FS, Aldammas FK, Sallam MS, Alotaibi AM. Comparison of 0.25% and 0.125% bupivacaine in hyperthermic intraperitoneal chemotherapy (HIPEC): a single-center experience. Annals of Middle Eastern Medicine. 2026;2(5):682-688. doi:10.24911/amem.15-3168
BibTeX
@article{Alhabib2026,
author = {Alhabib, Rasheed and Tulbah, Mohammad and Albishri, Faisal S. and Aldammas, Fatma K. and Sallam, Moath S. and Alotaibi, Abdulkareem M.},
title = {Comparison of 0.25% and 0.125% bupivacaine in hyperthermic intraperitoneal chemotherapy (HIPEC): a single-center experience},
journal = {Annals of Middle Eastern Medicine},
year = {2026},
volume = {2},
number = {5},
pages = {682--688},
doi = {10.24911/amem.15-3168}
}
EUVIMED